Ovarian Serous Surface Papillary Adenocarcinoma
5 clinical trials · Condition
◉ Watch Ovarian Serous Surface Papillary Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT02283658) | Mayo Clinic | 2014-11-14 |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02101775) | National Cancer Institute (NCI) | 2014-07-21 |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648) | National Cancer Institute (NCI) | 2010-04-14 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (NCT01010126) | National Cancer Institute (NCI) | 2009-09-08 |
| Research Study in Patients With Advanced Ovarian Epithelial Cancer (NCT00053235) | Gynecologic Oncology Group | 2002-11-01 |
Track Ovarian Serous Surface Papillary Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.